Nurix Therapeutics is a biopharmaceutical company developing targeted protein degradation medicines designed to treat cancer and inflammatory diseases by selectively removing disease-causing proteins. The company commercializes its drug candidates through major partnerships with Gilead Sciences, Sanofi, and Pfizer, generating non-dilutive revenue and milestone payments while retaining development and commercialization rights to its own pipeline. Nurix's proprietary DEL-AI platform—an artificial intelligence-integrated discovery engine combining DNA-encoded library screening, automated chemistry, and machine learning—identifies and optimizes degrader molecules that bind protein-degradation machinery to eliminate target proteins, offering advantages over traditional small-molecule inhibitors including broader target applicability, lower mutation resistance, and the ability to address previously undruggable disease mechanisms.